基线浆细胞基因特征预测系统性硬化症皮肤评分对伊奈利珠单抗(MEDI-551)治疗的改善,并与系统性红斑狼疮和慢性阻塞性肺疾病疾病活动度相关
在两项I期临床试验中评估系统性硬化症(SSc)皮肤活检的浆细胞基因特征,发现SSc皮肤中该特征较健康供者皮肤升高(P=2.28×10-6),且与基线改良Rodnan皮肤厚度评分(MRSS)相关(r=0.64,P=0.0004)。基线浆细胞特征高的患者接受抗CD19药物伊奈利珠单抗(MEDI-551)治疗后MRSS改善更明显(平均±标准差变化35±16%;P=6.30×10-4),高于基线低特征患者(8±12%;P=0.104)。该特征在SLE、DM、COPD、间质性肺病和IPF组织中过表达,并与SLE疾病活动和COPD肺气肿程度相关。
要点
- SSc皮肤浆细胞基因特征较健康皮肤升高,且与基线MRSS相关(r=0.64)。
- 基线浆细胞特征高者接受伊奈利珠单抗后MRSS改善35±16%,低者改善8±12%。
- 浆细胞特征在SLE、DM、COPD、ILD和IPF组织中过表达(倍数变化>2)。
核心结论
- 结果支持浆细胞在SSc及其他自身免疫或肺部适应症发病中起作用。
- 治疗前浆细胞特征升高与SSc患者从MEDI-551获得更多获益相关。
研究设计与样本
- 在两项I期临床试验的SSc皮肤活检样本中评估浆细胞基因特征。
- 评估公共研究中COPD、IPF、DM、SLE和特应性皮炎组织以及SLE IIb期临床试验血液的微阵列数据。
主要发现
- SSc皮肤标本浆细胞特征较健康供者皮肤升高(P=2.28×10-6),并与基线MRSS相关(r=0.64,P=0.0004)。
- 基线浆细胞特征高的患者接受伊奈利珠单抗(MEDI-551)后MRSS平均±标准差变化35±16%(P=6.30×10-4),高于基线低特征患者的8±12%(P=0.104)。
- 浆细胞特征在SLE、DM、COPD、间质性肺病和IPF组织中相对对照过表达(所有倍数变化>2;P<0.001)。
- 浆细胞特征在轻中度与重度SLE患者间差异显著(SLE疾病活动指数切点10)(倍数变化1.44;P=3.90×10-3)。
- 浆细胞特征与COPD肺气肿程度显著相关(r=0.53,P=7.55×10-8)。
关键数值与推荐
- SSc皮肤浆细胞特征较健康供者皮肤升高P=2.28×10-6。
- 浆细胞特征与基线MRSS相关r=0.64,P=0.0004。
- 高浆细胞特征组伊奈利珠单抗后MRSS变化35±16%(P=6.30×10-4),低特征组8±12%(P=0.104)。
- SLE轻中度与重度(SLE疾病活动指数切点10)间浆细胞特征倍数变化1.44,P=3.90×10-3。
- COPD肺气肿程度与浆细胞特征相关r=0.53,P=7.55×10-8。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: B cells impact the progression of systemic sclerosis (SSc; scleroderma) through multiple pathogenic mechanisms. CD19 inhibition in mice reduced skin thickness, collagen production, and autoantibody levels, consistent with CD19 expression on plasma cells (PCs), the source of antibody production. PC depletion could effectively reduce collagen deposition and inflammation in SSc; therefore, we investigated the effects of PC depletion on SSc disease activity. METHODS: A PC gene signature was evaluated in SSc skin biopsy samples in 2 phase I clinical trials. We assessed microarray data from tissue from public studies of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), dermatomyositis (DM), systemic lupus erythematosus (SLE), and atopic dermatitis, as well as blood from a phase IIb clinical trial in SLE. RESULTS: The PC signature was elevated in SSc skin specimens compared to healthy donor skin (P = 2.28 × 10-6 ) and correlated with the baseline modified Rodnan skin thickness score (MRSS) (r = 0.64, P = 0.0004). Patients with a high PC signature at baseline showed greater improvement in the MRSS (mean ± SD change 35 ± 16%; P = 6.30 × 10-4 ) following anti-CD19 treatment with inebilizumab (MEDI-551) than did patients with a low PC signature at baseline (mean ± SD change 8 ± 12%; P = 0.104). The PC signature was overexpressed in tissue from patients with SLE, DM, COPD, interstitial lung disease, and IPF relative to controls (all fold change >2; P < 0.001). The PC signature also differed significantly between SLE patients with mild-to-moderate disease and those with severe disease (SLE Disease Activity Index cutoff at 10) (fold change 1.44; P = 3.90 × 10-3 ) and correlated significantly with the degree of emphysema in COPD (r = 0.53, P = 7.55 × 10-8 ). CONCLUSION: Our results support the notion that PCs have a role in the pathogenesis of SSc and other autoimmune or pulmonary indications. An elevated pretreatment PC signature was associated with increased benefit from MEDI-551 in SSc.
引用
- Streicher K, Sridhar S, Kuziora M, et al. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease. Arthritis Rheumatol. 2018. PMID: 29956883. doi:10.1002/art.40656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。